期刊
AGING CLINICAL AND EXPERIMENTAL RESEARCH
卷 29, 期 1, 页码 29-34出版社
SPRINGER
DOI: 10.1007/s40520-016-0708-1
关键词
Aging; Physical performance; Markers; Multivariate analysis; Skeletal muscle; Disability
资金
- Innovative Medicines Initiative-Joint Undertaking [IMI-JU 115621]
- Centro Studi Achille e Linda Lorenzon
- Fondazione Roma
- Catholic University of the Sacred Heart
- European Federation of Pharmaceutical Industries and Associations ( EFPIA)
Physical frailty (PF) and sarcopenia are major health issues in geriatric populations, given their high prevalence and association with several adverse outcomes. Nevertheless, the lack of an univocal operational definition for the two conditions has so far hampered their clinical implementation. Existing definitional ambiguities of PF and sarcopenia, together with their complex underlying pathophysiology, also account for the absence of robust biomarkers that can be used for screening, diagnostic and/or prognostication purposes. This review provides an overview of currently available biological markers for PF and sarcopenia, as well as a critical appraisal of strengths and weaknesses of traditional procedures for biomarker development in the field. A novel approach for biomarker identification and validation, based on multivariate methodologies, is also discussed. This strategy relies on the multidimensional modeling of complementary biomarkers to cope with the phenotypical and pathophysiological complexity of PF and sarcopenia. Biomarkers identified through the implementation of multivariate strategies may be used to support the detection of the two conditions, track their progression over time or in response to interventions, and reveal the onset of complications (e.g., mobility disability) at a very early stage.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据